1 – 9 of 9
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2017
-
Mark
Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer : the Danish cohort of BIG 1-98
(
- Contribution to journal › Article
- 2009
-
Mark
Validation of the predictive value of tissue inhibitor of metalloproteinases-1 for the response to first-line chemotherapy in metastatic breast cancer.
(
- Contribution to journal › Published meeting abstract
-
Mark
TIMP-1 and responsiveness of estrogen receptor negative breast cancer to preoperative epirubicin and cyclophosphamide with or without gefitinib
(
- Contribution to journal › Published meeting abstract
- 2006
-
Mark
Continuous versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first line endocrine treatment in advanced breast cancer: An EORTC phase III study (10863)
(
- Contribution to journal › Article
-
Mark
Reduced mortality for women with mammography-detected breast cancer in east Denmark and south Sweden
(
- Contribution to journal › Article
- 2003
-
Mark
Prognostic value of quality of life scores for time to progression (TTP) and overall survival time (OS) in advanced breast cancer
(
- Contribution to journal › Article
- 2002
-
Mark
Physical performance, toxicity, and quality of life as assessed by the physician and the patient
(
- Contribution to journal › Article
- 2001
-
Mark
Timing of quality of life (QoL) assessments as a source of error in oncological trials
(
- Contribution to journal › Article
- 2000
-
Mark
Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5-fluorouracil. A multicentre randomised phase III trial by the Scandinavian breast group
(
- Contribution to journal › Article